Trials / Completed
CompletedNCT02252536
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 346 (actual)
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NIH
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gabapentin enacarbil | Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day |
| DRUG | Placebo | Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2014-09-30
- Last updated
- 2018-11-14
- Results posted
- 2018-09-21
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02252536. Inclusion in this directory is not an endorsement.